Clinical Trial: Neoadjuvant Lu-177-PSMA-617 in Patients with High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798558) titled 'Neoadjuvant Lu-177-PSMA-617 in Patients with High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy' on Jan. 17.

Brief Summary: Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy score of Gleason 8 (GS8) (Grade group 4 [GG4]) or higher. Patients also need to have a positive PSMA scan on 68-Ga-PSMA-11 PET/CT scan.

Study Start Date: Jan., 2025

Study Type: I...